Auspex Pharmaceuticals, a Vista, Calif.-based biotech startup focused on targeted deuteration of clinically validated drugs, has raised $13.88 million in Series B funding. Thomas, McNerney & Partners led the round, and was joined by return backers CMEA Ventures and Costa Verde Capital. www.auspexpharma.com
Nearly there!
We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case
it’s been delivered there.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.